HYTN Innovations Inc.

Equities

HYTN

CA40443L1040

Non-Alcoholic Beverages

Market Closed - Canadian Securities Exchange 17:11:04 28/06/2024 BST 5-day change 1st Jan Change
0.36 CAD -2.70% Intraday chart for HYTN Innovations Inc. +4.35% +414.29%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
HYTN Awarded Drug Establishment License from Health Canada MT
HYTN Innovations Inc. Receives Drug Establishment License from Health Canada, Expanding GMP Capabilities CI
HYTN Innovations Inc. entered into purchase agreement to acquire Prism Scientific Labs Inc for CAD 4.7 million. CI
HYTN Innovations Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
HYTN Innovations Inc. announced that it has received CAD 0.74855 million in funding CI
HYTN Innovations Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
HYTN Innovations Inc. Announces Expansion of 100 MG Nano Shot Citrus to Western Canada CI
HYTN Innovations Inc. announced that it expects to receive CAD 1 million in funding CI
HYTN Innovations Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
HYTN Innovations Inc. announced that it has received CAD 0.505 million in funding CI
HYTN Innovations Inc. announced that it expects to receive CAD 1 million in funding CI
HYTN Innovations Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
HYTN Innovations Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Hytn Innovations Inc. Announces Board Resignations CI
Hytn Innovations Inc. Submits an Amendment to Its Controlled Drugs and Substances Dealers License with Health Canada CI
HYTN Innovations Inc. Expands its Controlled Drugs and Substances Dealers License to Include Mdma and Ketamine CI
HYTN Innovations Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
HYTN Innovations Cultivates Psilocybin Mushrooms and Upgrades Equipment for API Development CI
HYTN Innovations Inc. Auditor Raises 'Going Concern' Doubt CI
HYTN Innovations Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Hytn Innovations Inc. Announces That Its Wholly Owned Subsidiary, Hytn Cannabis Inc. Enters into Sales, Distribution and Marketing Agreement with Rose Lifescience Inc CI
Hytn Opens Provincial and Territorial Markets for Tricanna Manufactured Pre-Rolled Cannabis Products CI
HYTN Cannabis Inc Announces Launch of Rapid Onset Nano Gummies CI
HYTN Secures Cannabis Cultivation License to Elevate the Quality of Its Cannabis Inputs CI
HYTN Grows Exports with Cannabis Flower Sales to Australia CI
Chart HYTN Innovations Inc.
More charts
HYTN Innovations Inc. is a Canada-based company that creates products containing psychoactive and psychotropic compounds, including cannabinoids derived from cannabis. The Company formulates, manufactures, markets, and sells cannabis goods. It is engaged in the development of the sparkling tetrahydrocannabinol and the cannabidiol beverage business. All its sparkling cannabis beverages contain 10 milligrams (mg) of THC and are made using its process, Elevation Technology. Its products include Rosewater Lemonade, Watermelon Mint, Lemongrass Ginger, and Blood Orange. Its Rosewater Lemonade is a sugar-free exploration of citrus accented with floral notes. Blood Orange is formulated to bring out the sweet flavors found in this seasonal citrus fruit. Its activities are focused on a single production and manufacturing facility, based in Kelowna, British Columbia. The Company’s subsidiaries include HYTN Innovations Inc., HYTN Beverage Corp, HYTN Cannabis Inc., and 1306562 B.C. Ltd.
More about the company
  1. Stock Market
  2. Equities
  3. HYTN Stock
  4. News HYTN Innovations Inc.
  5. HYTN Awarded Drug Establishment License from Health Canada